Fresenius Medical Care Q2 results show revenue growth despite challenges

Published 05/08/2025, 08:28
© Reuters.

Investing.com -- Fresenius Medical (TASE:BLWV) Care (NYSE:FMS) on Tuesday reported second-quarter 2025 revenue of €4,792 million, in line with consensus estimates of €4,750 million, representing 5% growth at constant exchange rates.

The company’s adjusted EBIT came in at €476 million, approximately 3% below consensus expectations of €492 million.

Performance was impacted by a severe flu season and excess mortality, which resulted in "stable" same market treatment growth.

Fresenius Medical Care confirmed its full-year 2025 outlook, projecting positive to low single-digit constant currency revenue growth and adjusted EBIT growth in the high teens to high twenties percentage range.

The adjusted EBIT guidance implies a narrowed margin of approximately 11-12%, compared to the previous 10-14% range.

The company’s net leverage ratio decreased to 2.7x from 2.8x in the first quarter, falling below its self-imposed target corridor of 3.0-3.5x.

In the Care Delivery segment, sales grew 1.3% at constant exchange rates, with 0.5% same market treatment growth.

The Value-Based Care segment saw sales increase by 28.4%, primarily driven by a substantial increase in member months following contract expansions.

Care Enablement revenue grew by 3.4% at constant exchange rates, driven by global volume growth and positive pricing momentum.

The FME25 savings program delivered €58 million in savings during the second quarter, with €53 million related to one-time costs.

The program remains on track to reach €180 million in savings for fiscal year 2025 and €1.05 billion by the end of 2027.

Management confirmed a €1 billion share buyback program over two years, with the first tranche starting in August.

The company also recently provided an aspirational 2030 Group adjusted EBIT margin target of "mid-teens" compared to the "11-12%" guidance for fiscal year 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.